Business
Agenus Corporate Update and First Quarter 2022 Financial Report
Botensilimab data to be presented and Phase 2 trials to launch.AGEN1571 (ILT2) clinical trials to commence and data presented at AACR.AGEN2373 progressing in
About this update from Agenus Inc.
[{"type":"text","content":"Botensilimab data to be presented and Phase 2 trials to launch.AGEN1571 (ILT2) clinical trials to commence and data presented at AACR.AGEN2373 progressing in the clinic and Gilead milestone payment received. LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today provided a corporate update and reported financial results for the first quarter 2022. “In the current challenging environment for the biotech industry, we are prioritizing our most promising clinical programs, including botensilimab combinations, as well as preclinical programs with the highest potential for engagement from collaborators,” said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus. “Needless to say, we are also taking decisive steps to contain costs across the board despite our reasonable cash position.” Botensilimab, Agenus’ innate and adaptive immune stimulator, to advance to Phase 2 Present updated data from our ongoing development program in the 3rd quarter.Phase 2 clinical studies to commence in colorectal, melanoma, and pancreatic cancers.All trials designed to demonstrate superiority to other immunotherapies and/or other standards of care.In addition, trials are designed to show benefit in cold tumors in combination with chemotherapy. AGEN1571 clinical trials to commence; preclinical data presented at AACR Agenus’ first myeloid-targeting agent.Overcomes the suppression of anti-tumor response via the ILT2 pathway which drives resistance to CTLA-4 and PD-1 directed therapies.Rationale is further validated by the durable clinical responses achieved in PD-1 resistant cancers with an ILT4 antagonist discovered by Agenus and licensed to Merck.Provides advantages in enhanced activation of T, NK and NKT cells and a superior ability to switch myeloid cells to a pro-inflammatory state.Phase 1 study to commence. Milestone payment received from Gilead for the clinical advancement of AGEN2373 targeting CD137 Another key pathway for antitumor immunity with enhancement of T cell and NK cell proliferation, cytokine secretion, and cellular cytotoxicity.Phase 1b combination study with botensilimab ongoing in melanoma patients who have relapsed or are refractory to prior anti-PD-1 therapy.G...